Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308786 · ClinicalTrials.gov registry record · Phase 2
HIV Reservoir Reduction With Interleukin-2
A Phase 2 study, sponsored by Case Western Reserve University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03308786: Clinical Trial Phase 2 study, sponsored by Case Western Reserve University.
NCT03308786 is a Phase 2 study that was terminated before completion, run by Case Western Reserve University. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03308786, a Phase 2 study, was terminated before completion, sponsored by Case Western Reserve University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV infection (viral load \<50 copies/mL).
Primary Outcome
Change in the number of infectious units per million resting CD4+ T cells (IUPM) from baseline to the end of study treatment, as measured by the Quantitative Viral Outgrowth Assay (QVOA).
Interventions
- DRUG Recombinant Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Why NCT03308786 stopped before completion
NCT03308786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Recombinant Interleukin-2 is the first listed.
NCT03308786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03308786 about?
NCT03308786 is a clinical study titled "HIV Reservoir Reduction With Interleukin-2". The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV in...
What is the current status of trial NCT03308786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-04-01. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT03308786?
The interventions under investigation include: Recombinant Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT03308786?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03308786's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI